Showing 1 - 10 of 536
protection. We use new survey data from India, the results of interviews with industry, government and multinational institutions …
Persistent link: https://www.econbiz.de/10012471281
. Using India as an example, it then brings together information gathered from both published sources and personal interviews …
Persistent link: https://www.econbiz.de/10012472451
tuberculosis drug samples that claim to be made in India and were sold in Africa, India, and five mid-income non-African countries … in India or non-African countries. Since this finding is robust for manufacturer-drug fixed effects, one likely …
Persistent link: https://www.econbiz.de/10012458199
We characterize how firms structure supply chains under climate risk. Using new data on the universe of firm-to-firm transactions from an Indian state, we show that firms diversify sourcing locations, and suppliers exposed to climate risk charge lower prices. Our event-study analysis finds that...
Persistent link: https://www.econbiz.de/10014512072
We characterize what features make supply chains more resilient. Using new data on the universe of firm-to-firm transactions from an Indian state, we identify firms with larger supplier risk following the Covid-19 lockdowns. Using an event-study design we find firms with suppliers in...
Persistent link: https://www.econbiz.de/10013462737
We examine the role of consumption externalities in the demand for pharmaceuticals at both the brand level and over a therapeutic class of drugs. These effects emerge when use of a drug by others affects its value, and/or conveys information abut efficacy and safety to patients and physicians....
Persistent link: https://www.econbiz.de/10012470978
Recent work linking the adoption of key organizational practices to productivity raises an important question: if adoption increases productivity so dramatically, why does adoption across an industry take so long? This paper explores this question in the context of one particularly interesting...
Persistent link: https://www.econbiz.de/10012471425
We examine the role of network effects in the demand for pharmaceuticals at both the brand level and for a therapeutic class of drugs. These effects emerge when use of a drug by others conveys information about its efficacy and safety to patients and physicians. This can lead to herd behavior...
Persistent link: https://www.econbiz.de/10012471776
After receiving FDA approval, a generic drug manufacturer can launch "at risk" before conclusion of any patent infringement litigation, but it risks paying damages if it loses. The generic can eliminate the risk by waiting to launch until the appeals process is complete but waiting has downsides...
Persistent link: https://www.econbiz.de/10012616579
Puerto Rico operated as a tax haven under U.S. Internal Revenue Code (IRC) Section 936. Firms in the pharmaceutical industry accounted for approximately 50% of tax credits awarded and 20% of employment under the program. The U.S. Congress eliminated the tax exemption program in 2006, creating a...
Persistent link: https://www.econbiz.de/10012599397